Header Logo

MICHAEL E RYTTING

TitleProfessor
InstitutionMD Anderson
DepartmentPediatrics
Address1515 Holcombe Blvd
Houston TX 77030-4009
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Baig MU, Rytting M, Roth M, Morani AC, Nunez C, Lin P, Cuglievan B. Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma. J Pediatr Hematol Oncol. 2021 Oct 01; 43(7):e991-e996. PMID: 33480649.
      Citations: 1     Fields:    Translation:Humans
    2. Gibson A, Hernandez C, Tejada FNH, Kawedia J, Rytting M, Cuglievan B. Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current Perspectives. Paediatr Drugs. 2021 Sep; 23(5):457-463. PMID: 34351604.
      Citations:    Fields:    Translation:Humans
    3. Cabrera TB, Wang W, Yedururi S, Slopis JM, Steiner RE, Rytting ME, Cuglievan B. Coincidental Expression of Classic Hodgkin Lymphoma and Neurofibromatosis Type I and Literature Review. J Pediatr Hematol Oncol. 2021 05 01; 43(4):e535-e538. PMID: 32366782.
      Citations:    Fields:    Translation:Humans
    4. Tambaro FP, Singh H, Jones E, Rytting M, Mahadeo KM, Thompson P, Daver N, DiNardo C, Kadia T, Garcia-Manero G, Chan T, Shah RR, Wierda WG. Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. Leukemia. 2021 11; 35(11):3282-3286. PMID: 33833386; PMCID: PMC8550958.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    5. Kucine N, Bergmann S, Krichevsky S, Jones D, Rytting M, Jain J, Bennett CM, Resar LMS, Mascarenhas J, Verstovsek S, Hoffman R. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia. Pediatr Blood Cancer. 2021 03; 68(3):e28888. PMID: 33381905; PMCID: PMC9040312.
      Citations:    Fields:    Translation:Humans
    6. Khatua S, Cooper LJN, Sandberg DI, Ketonen L, Johnson JM, Rytting ME, Liu DD, Meador H, Trikha P, Nakkula RJ, Behbehani GK, Ragoonanan D, Gupta S, Kotrotsou A, Idris T, Shpall EJ, Rezvani K, Colen R, Zaky W, Lee DA, Gopalakrishnan V. Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. Neuro Oncol. 2020 08 17; 22(8):1214-1225. PMID: 32152626; PMCID: PMC7594549.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    7. Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2020 04; 20(4):212-218. PMID: 32035785.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    8. Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018 08 18; 392(10147):593-606. PMID: 30078459; PMCID: PMC10230947.
      Citations: 165     Fields:    Translation:Humans
    9. Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):230-234. PMID: 28859185; PMCID: PMC5838597.
      Citations: 43     Fields:    Translation:HumansCellsCTClinical Trials
    10. Patel RP, Sitton CW, Ketonen LM, Hou P, Johnson JM, Romo S, Fletcher S, Shah MN, Kerr M, Zaky W, Rytting ME, Khatua S, Sandberg DI. Phase-contrast cerebrospinal fluid flow magnetic resonance imaging in qualitative evaluation of patency of CSF flow pathways prior to infusion of chemotherapeutic and other agents into the fourth ventricle. Childs Nerv Syst. 2018 03; 34(3):481-486. PMID: 29170836.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    11. Pemmaraju N, Rytting ME. Questions on asparaginase-associated pancreatitis. Lancet Oncol. 2017 09; 18(9):1148-1149. PMID: 28884687.
      Citations: 2     Fields:    Translation:Humans
    12. Cuglievan B, Menegaz BA, Garces S, Rytting ME. Acute myeloid leukaemia masquerading as a primary CNS tumour. BMJ Case Rep. 2017 Aug 11; 2017. PMID: 28801332; PMCID: PMC5623295.
      Citations: 1     Fields:    Translation:Humans
    13. Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, Daver N, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, DiNardo CD, Bivins C, McCue D, Richie MA, Ravandi F. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol. 2018 08; 182(3):442-444. PMID: 28616864; PMCID: PMC6511975.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    14. Rytting ME, Jabbour EJ, O'Brien SM, Kantarjian HM. Acute lymphoblastic leukemia in adolescents and young adults. Cancer. 2017 Jul 01; 123(13):2398-2403. PMID: 28328172.
      Citations: 16     Fields:    Translation:Humans
    15. Cuglievan B, Menegaz BA, DePombo A, Morani AC, Miranda RN, Rytting M. A pediatric patient with glycogen storage disease type IA and Castleman disease. Pediatr Blood Cancer. 2017 08; 64(8). PMID: 28035790.
      Citations:    Fields:    Translation:Humans
    16. Rytting ME, Jabbour EJ, Jorgensen JL, Ravandi F, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Borthakur G, Garris R, Wang S, Pierce S, Schroeder K, Kornblau SM, Thomas DA, Cortes JE, O'Brien SM, Kantarjian HM. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M?nster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen. Am J Hematol. 2016 08; 91(8):819-23. PMID: 27178680; PMCID: PMC5558853.
      Citations: 36     Fields:    Translation:HumansCells
    17. Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, Daver NG. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer. 2016 09 15; 122(18):2857-66. PMID: 27244347; PMCID: PMC5014667.
      Citations: 30     Fields:    Translation:Humans
    18. Jain N, Lamb AV, O'Brien S, Ravandi F, Konopleva M, Jabbour E, Zuo Z, Jorgensen J, Lin P, Pierce S, Thomas D, Rytting M, Borthakur G, Kadia T, Cortes J, Kantarjian HM, Khoury JD. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016 Apr 14; 127(15):1863-9. PMID: 26747249; PMCID: PMC4915808.
      Citations: 90     Fields:    Translation:HumansCells
    19. Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 01; 121(23):4158-64. PMID: 26308885; PMCID: PMC4666803.
      Citations: 61     Fields:    Translation:HumansCellsCTClinical Trials
    20. Sandberg DI, Rytting M, Zaky W, Kerr M, Ketonen L, Kundu U, Moore BD, Yang G, Hou P, Sitton C, Cooper LJ, Gopalakrishnan V, Lee DA, Thall PF, Khatua S. Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial. J Neurooncol. 2015 Oct; 125(1):133-41. PMID: 26255071; PMCID: PMC4592494.
      Citations: 9     Fields:    Translation:Humans
    21. DeWire M, Fouladi M, Turner DC, Wetmore C, Hawkins C, Jacobs C, Yuan Y, Liu D, Goldman S, Fisher P, Rytting M, Bouffet E, Khakoo Y, Hwang EI, Foreman N, Stewart CF, Gilbert MR, Gilbertson R, Gajjar A. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). J Neurooncol. 2015 May; 123(1):85-91. PMID: 25859842; PMCID: PMC4992988.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    22. Daver N, Boumber Y, Kantarjian H, Ravandi F, Cortes J, Rytting ME, Kawedia JD, Basnett J, Culotta KS, Zeng Z, Lu H, Richie MA, Garris R, Xiao L, Liu W, Baggerly KA, Jabbour E, O'Brien S, Burger J, Bendall LJ, Thomas D, Konopleva M. A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Clin Cancer Res. 2015 Jun 15; 21(12):2704-14. PMID: 25724525; PMCID: PMC4470787.
      Citations: 23     Fields:    Translation:HumansCellsCTClinical Trials
    23. Silva JG, Corrales-Medina FF, Maher OM, Tannir N, Huh WW, Rytting ME, Subbiah V. Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations. Oncoscience. 2015; 2(2):187-92. PMID: 25859559; PMCID: PMC4381709.
      Citations: 9     
    24. Daver N, Thomas D, Ravandi F, Cortes J, Garris R, Jabbour E, Garcia-Manero G, Borthakur G, Kadia T, Rytting M, Konopleva M, Kantarjian H, O'Brien S. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015 May; 100(5):653-61. PMID: 25682595; PMCID: PMC4420214.
      Citations: 61     Fields:    Translation:HumansCTClinical Trials
    25. Jabbour E, O'Brien S, Huang X, Thomas D, Rytting M, Sasaki K, Cortes J, Garcia-Manero G, Kadia T, Ravandi F, Pierce S, Kantarjian H. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol. 2015 Mar; 90(3):193-6. PMID: 25407953; PMCID: PMC5505232.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    26. Owusu-Agyemang P, Borthakur G, Rebello E, Arunkumar R, Wang SA, Rytting M, Jorgensen JL, Hernandez M, Ruiz JR, Cata JP. The association between opioid administration and response to therapy in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2015 Jun; 56(6):1903-5. PMID: 25363399.
      Citations: 1     Fields:    Translation:Humans
    27. Kawedia JD, Rytting ME. Asparaginase in acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2014 Sep; 14 Suppl:S14-7. PMID: 25486949.
      Citations: 20     Fields:    Translation:Humans
    28. Benton CB, Thomas DA, Yang H, Ravandi F, Rytting M, O'Brien S, Franklin AR, Borthakur G, Dara S, Kwari M, Pierce SR, Jabbour E, Kantarjian H, Garcia-Manero G. Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 Nov; 167(3):356-65. PMID: 25066676; PMCID: PMC4198465.
      Citations: 16     Fields:    Translation:HumansCellsCTClinical Trials
    29. Rytting ME, Thomas DA, O'Brien SM, Ravandi-Kashani F, Jabbour EJ, Franklin AR, Kadia TM, Pemmaraju N, Daver NG, Ferrajoli A, Garcia-Manero G, Konopleva MY, Cortes JE, Borthakur G, Garris R, Cardenas-Turanzas M, Schroeder K, Jorgensen JL, Kornblau SM, Kantarjian HM. Augmented Berlin-Frankfurt-M?nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer. 2014 Dec 01; 120(23):3660-8. PMID: 25042398; PMCID: PMC4239168.
      Citations: 29     Fields:    Translation:Humans
    30. Rytting M. Acting on minimal residual disease in ALL. Lancet Oncol. 2014 Jul; 15(8):777-8. PMID: 24924992.
      Citations:    Fields:    Translation:Humans
    31. Piha-Paul SA, Shin SJ, Vats T, Guha-Thakurta N, Aaron J, Rytting M, Kleinerman E, Kurzrock R. Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus. Anticancer Res. 2014 Apr; 34(4):1939-45. PMID: 24692729; PMCID: PMC5685166.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    32. Rytting M, Triche L, Thomas D, O'Brien S, Kantarjian H. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014 Feb; 61(2):369-72. PMID: 24000241; PMCID: PMC5042143.
      Citations: 21     Fields:    Translation:Humans
    33. Pinto-Patarroyo GP, Rytting ME, Vierling JM, Suarez-Almazor ME. Haemophagocytic lymphohistiocytosis presenting as liver failure following Epstein-Barr and prior hepatitis A infections. BMJ Case Rep. 2013 Aug 13; 2013. PMID: 23943807; PMCID: PMC3761427.
      Citations: 7     Fields:    Translation:Humans
    34. DiNardo CD, Gharibyan V, Yang H, Wei Y, Pierce S, Kantarjian HM, Garcia-Manero G, Rytting M. Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia. Am J Hematol. 2013 Sep; 88(9):784-9. PMID: 23757320; PMCID: PMC3947930.
      Citations: 7     Fields:    Translation:HumansCells
    35. Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, York S, Ravandi F, Garris R, Kwari M, Faderl S, Cortes J, Champlin R, O'Brien S. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 01; 119(15):2728-36. PMID: 23633004; PMCID: PMC3720844.
      Citations: 95     Fields:    Translation:HumansCTClinical Trials
    36. Georgiadou SP, Pongas G, Fitzgerald NE, Lewis RE, Rytting M, Marom EM, Kontoyiannis DP. Invasive Mold Infections in Pediatric Cancer Patients Reflect Heterogeneity in Etiology, Presentation, and Outcome: A 10-Year, Single-Institution, Retrospective Study. J Pediatric Infect Dis Soc. 2012 Jun; 1(2):125-35. PMID: 26619165.
      Citations: 12     Fields:    
    37. Rytting ME. Lessons from ALL-REZ BFM 90: therapy for childhood leukemia based on timing and site of relapse. Curr Hematol Malig Rep. 2012 Mar; 7(1):1-2. PMID: 22290023.
      Citations:    Fields:    
    38. Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012 Apr; 13(4):403-11. PMID: 22357140.
      Citations: 136     Fields:    Translation:HumansCTClinical Trials
    39. Fontanilla HP, Pinnix CC, Ketonen LM, Woo SY, Vats TS, Rytting ME, Wolff JE, Mahajan A. Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol. 2012 Feb; 35(1):51-7. PMID: 21297433.
      Citations: 25     Fields:    Translation:Humans
    40. Wolff JE, Brown RE, Buryanek J, Pfister S, Vats TS, Rytting ME. Preliminary experience with personalized and targeted therapy for pediatric brain tumors. Pediatr Blood Cancer. 2012 Jul 15; 59(1):27-33. PMID: 22162424.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    41. Subbiah V, Wolff J, Ketonen L, Ellezam B, Rytting ME. Advanced atypical teratoid/rhabdoid tumor (ATRT) treated with intensive multimodal approach shows continued response to sarcoma type salvage therapy. Pediatr Blood Cancer. 2012 May; 58(5):823-4. PMID: 21922648.
      Citations:    Fields:    Translation:Humans
    42. Lockhart S, McDonald L, Rytting M, Chan KW. Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ ALL resolution after decitabine therapy. Pediatr Blood Cancer. 2012 Sep; 59(3):573-5. PMID: 21910215.
      Citations: 1     Fields:    Translation:HumansCells
    43. Wolff JE, Rytting ME, Vats TS, Zage PE, Ater JL, Woo S, Kuttesch J, Ketonen L, Mahajan A. Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience. J Neurooncol. 2012 Jan; 106(2):391-7. PMID: 21858608; PMCID: PMC3990187.
      Citations: 29     Fields:    Translation:Humans
    44. Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L, Kovacsovics T, Litzow M, Rytting M, Borthakur G, Bleyer A. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011 Dec; 52(12):2237-53. PMID: 21827361.
      Citations: 64     Fields:    Translation:Humans
    45. Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. Cancer. 2012 Feb 01; 118(3):848-55. PMID: 21751205; PMCID: PMC3919032.
      Citations: 7     Fields:    Translation:Humans
    46. Wolff JE, Rytting M, Vats T, Ater J, Mahajan A, Woo S, Ketonen L, Kuttesch J, Liu D, Thall P, Chang EL. Induction treatment for diffuse intrinsic pontine glioma, experience of M.D. Anderson Cancer Center. Anticancer Res. 2011 Jun; 31(6):2265-9. PMID: 21737651.
      Citations: 1     Fields:    Translation:Humans
    47. Faderl S, Thomas DA, O'Brien S, Ravandi F, Garcia-Manero G, Borthakur G, Ferrajoli A, Verstovsek S, Ayoubi M, Rytting M, Feliu J, Kantarjian HM. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):54-9. PMID: 21454191.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    48. Rytting M, Ravandi F, Estey E, Cortes J, Faderl S, Garcia-Manero G, Jeha S, Ouzounian S, Pierce S, Kantarjian H. Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study. Cancer. 2010 Nov 15; 116(22):5272-8. PMID: 20665501; PMCID: PMC5434864.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    49. Green HL, Rytting ME, Cox CS. A rapidly growing lymphoma and tumor lysis syndrome in a toddler. JAAPA. 2010 Aug; 23(8):30, 32-4. PMID: 20821911.
      Citations:    Fields:    Translation:Humans
    50. Bonate PL, Cunningham CC, Gaynon P, Jeha S, Kadota R, Lam GN, Razzouk B, Rytting M, Steinherz P, Weitman S. Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer. Cancer Chemother Pharmacol. 2011 Apr; 67(4):875-90. PMID: 20582417.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    51. Rytting M. Peg-asparaginase for acute lymphoblastic leukemia. Expert Opin Biol Ther. 2010 May; 10(5):833-9. PMID: 20345338.
      Citations: 21     Fields:    Translation:Humans
    52. Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R, Cooper T, Kadota R, Rytting M, Steinherz P, Shen V, Jeha S, Abichandani R, Carroll WL. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia. 2009 Dec; 23(12):2259-64. PMID: 19741725.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    53. Jeha S, Razzouk B, Rytting M, Rheingold S, Albano E, Kadota R, Luchtman-Jones L, Bomgaars L, Gaynon P, Goldman S, Ritchey K, Arceci R, Altman A, Stine K, Steinherz L, Steinherz P. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol. 2009 Sep 10; 27(26):4392-7. PMID: 19652076; PMCID: PMC2744276.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    54. Rytting ME, Kantarjian H, Albitar M. Acute lymphoblastic leukemia with Burkitt-like morphologic features and high myeloperoxidase activity. Am J Clin Pathol. 2009 Aug; 132(2):182-5; quiz 306. PMID: 19605811.
      Citations: 3     Fields:    Translation:Humans
    55. Ren Y, Medeiros LJ, Amin HM, Rytting ME, Jorgensen JL, Chen W. Unusual expression of CD94 on CD8+ TCR-alpha beta T cells in infectious mononucleosis. Ann Diagn Pathol. 2007 Feb; 11(1):55-60. PMID: 17240309.
      Citations:    Fields:    Translation:HumansCells
    56. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9. PMID: 16882711; PMCID: PMC1895437.
      Citations: 180     Fields:    Translation:HumansCellsCTClinical Trials
    57. Razzouk BI, Estey E, Pounds S, Lensing S, Pierce S, Brandt M, Rubnitz JE, Ribeiro RC, Rytting M, Pui CH, Kantarjian H, Jeha S. Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. Cancer. 2006 Jun 01; 106(11):2495-502. PMID: 16639734.
      Citations: 20     Fields:    Translation:Humans
    58. Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, Luchtman-Jones L, Rytting M, Bomgaars LR, Rheingold S, Ritchey K, Albano E, Arceci RJ, Goldman S, Griffin T, Altman A, Gordon B, Steinherz L, Weitman S, Steinherz P. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006 Apr 20; 24(12):1917-23. PMID: 16622268.
      Citations: 70     Fields:    Translation:HumansCTClinical Trials
    59. Corey SJ, Elopre M, Weitman S, Rytting ME, Robinson LJ, Rumelhart S, Goldman FD. Complete remission following clofarabine treatment in refractory juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol. 2005 Mar; 27(3):166-8. PMID: 15750451.
      Citations:    Fields:    Translation:Humans
    60. Bonate PL, Craig A, Gaynon P, Gandhi V, Jeha S, Kadota R, Lam GN, Plunkett W, Razzouk B, Rytting M, Steinherz P, Weitman S. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol. 2004 Nov; 44(11):1309-22. PMID: 15496649.
      Citations: 12     Fields:    Translation:Humans
    61. Rytting ME, Wierda WG. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy. Leuk Lymphoma. 2004 Aug; 45(8):1623-6. PMID: 15370215.
      Citations: 7     Fields:    Translation:Humans
    62. Rytting ME. Pediatric myelodysplastic syndromes. Curr Hematol Rep. 2004 May; 3(3):173-7. PMID: 15087064.
      Citations:    Fields:    Translation:Humans
    63. Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, Rytting M, Brandt M, Keating M, Plunkett W, Kantarjian H. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004 Feb 01; 103(3):784-9. PMID: 14551141.
      Citations: 73     Fields:    Translation:HumansCTClinical Trials
    64. Rytting M, Pearson P, Raymond AK, Ayala A, Murray J, Yasko AW, Johnson M, Jaffe N. Osteosarcoma in preadolescent patients. Clin Orthop Relat Res. 2000 Apr; (373):39-50. PMID: 10810461.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    65. Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, Culbert SJ, Danielson M, Jeha SS, Kuttesch JF, Rolston KV. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer. 1999 Jul 01; 86(1):126-34. PMID: 10391572.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    66. Ravandi F, Rytting ME, Osmon C, Braud EL, Roach RW, Edwards K, Winn R, Abbruzzese JL, Pazdur R. Phase II trial of 5-fluorouracil, folinic acid and recombinant alpha-2a-interferon in patients with advanced colorectal cancer. Anticancer Drugs. 1999 Jul; 10(6):519-24. PMID: 10885898.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    67. Mullen CA, Petropoulos D, Roberts WM, Rytting M, Zipf T, Chan KW, Culbert SJ, Danielson M, Jeha SS, Kuttesch JF, Rolston KV. Economic and resource utilization analysis of outpatient management of fever and neutropenia in low-risk pediatric patients with cancer. J Pediatr Hematol Oncol. 1999 May-Jun; 21(3):212-8. PMID: 10363854.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    68. Mullen CA, Petropoulos D, Rytting M, Jeha S, Zipf T, Roberts WM, Rolston KV. Acute reversible arthropathy in a pediatric patient with cancer treated with a short course of ciprofloxacin for febrile neutropenia. J Pediatr Hematol Oncol. 1998 Sep-Oct; 20(5):516-7. PMID: 9787333.
      Citations: 2     Fields:    Translation:Humans
    69. Rytting M, Worth L, Jaffe N. Hemolytic disorders associated with cancer. Hematol Oncol Clin North Am. 1996 Apr; 10(2):365-76. PMID: 8707760.
      Citations: 3     Fields:    Translation:HumansCells
    70. Methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors. Journal of Neuro-Oncology. 125:133-141.
    71. Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations. Oncoscience. 2:187-192.
    72. Invasive mold infections in pediatric cancer patients reflect heterogeneity in etiology, presentation, and outcome. Journal of the Pediatric Infectious Diseases Society. 1:125-135.
    73. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia. Pediatric Blood and Cancer. 61:369-372.
    74. Acute Lymphoblastic Leukemia in Adolescents and Young Adults. 244-249.
    75. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults. Blood. 127:1863-1869.
    76. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma. Journal of Neuro-Oncology. 123:85-91.
    77. A pediatric patient with glycogen storage disease type IA and Castleman disease. Pediatric Blood and Cancer.
    78. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer.
    79. A phase I/II study of the mTOR inhibitor everolimus in combination with hyperCVAD chemotherapy in patients with relapsed/refractory acute lymphoblastic leukemia. Clinical Cancer Research. 21:2704-2714.
    80. Langerhans cell histiocytosis with atypical histiocytic marrow infiltration. Blood. 124:11.
    RYTTING's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (281)
    Explore
    _
    Co-Authors (78)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _